Attovia Therapeutics, Inc.'s (NASDAQ:ATTO) Quiet Period To End on September 14thMarket Beat·6 hours agoATTO+5.58%GS+0.07%
Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRCrttnews·Sep 4 at 09:20 AMATTO+5.58%TVTX-1.89%
Attovia Therapeutics to Participate in Upcoming Investor ConferencesUnusual Whales·Sep 3 at 08:07 PMATTO+5.58%
Attovia's Q2 Loss Expands With Increased Trials For ATTO-1310; Plans Phase 2 For Q1 '27rttnews·Sep 3 at 04:50 PMATTO+5.58%
Sam Slutsky Reiterates Buy on Attovia, Maintains $45 Price Target on Strong Early ATTO-1310 Data and Robust Cash RunwayTip Ranks·Sep 3 at 03:55 PMATTO+5.58%
Attovia Therapeutics, Inc. GAAP EPS of -$4.88 misses by $4.25, revenue of $0.45Mbusinessinsider·Sep 2 at 08:31 PMATTO+5.58%
ATTO: Lead program shows clinical proof of concept; IPO funds extend cash runway into 2030Quartr·Sep 2 at 08:24 PMATTO+5.58%
Attovia Q2 FY26 net loss widens to $20.7 million; revenue rises to $0.5 millionPUBT·Sep 2 at 08:18 PMATTO+5.58%
Attovia Therapeutics (NASDAQ:ATTO) Upgraded by Royal Bank Of Canada to "Moderate Buy" RatingMarket Beat·Sep 1 at 10:30 AMATTO+5.58%
Morgan Stanley Begins Coverage on Attovia Therapeutics (NASDAQ:ATTO)Market Beat·Aug 31 at 12:06 PMATTO+5.58%BLK-0.34%
This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga_article·Aug 31 at 11:46 AMTP+1.01%BRVE+1.79%
Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC CapitalTip Ranks·Aug 31 at 06:25 AMATTO+5.58%
